TICKERNERD
Menu
ALKSALKSHealthcare · Drug Manufacturers - Specialty & Generic

ALKS Stock Forecast: Alkermes Plc Price Predictions for 2026-2027

Last close, 11 Sept 2026
$46
−0.30% on the day

The 18 Wall Street analysts covering Alkermes Plc hold a median 12-month price target of $58 — +26.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 62 of 100 as at 12 Sept 2026 — in the upper half.

Market cap
$7.7B
Ticker Nerd rank
62 / 100
Median analyst target
$58
Analysts covering
18
Revenue$392.9M+28.2% y/y
Operating income−$48.3M
Net income−$66.5M
Free cash flow−$169.8M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.9%
1M
−6.6%
YTD
+64.3%
1Y
+65.9%
From 52W high
−16.8%
From 52W low
+73.3%
$27
$55
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALKS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alkermes Plc on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
62 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
98
Volatility
97
Momentum
86
Quality
83
Revisions
49
Growth
40
Accruals
38
Issuance
22
Size
18

Value (98): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (22): The company has been issuing shares or taking on financing, diluting existing holders.

Size (18): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALKS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALKS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$30$40$50$60$70Oct 25Jan 26Apr 26Jul 26ALKSHigh $72Median $58Low $38

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says18 analysts
14 Buy3 Hold1 Sell
Low $38Median $58High $72

The green dot is the last close — the median target sits +26.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 5 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
29 July 2026BairdMaintainsOutperform$48 → $58
29 July 2026JP MorganMaintainsNeutral$60 → $61
28 July 2026Piper SandlerReiteratesOverweight$43 → $65
20 July 2026StifelReiteratesBuy$45 → $63
20 July 2026StifelReiteratesBuy—
13 July 2026JP MorganReinstatesNeutral$60
13 July 2026NeedhamMaintainsBuy$61 → $62
13 July 2026NeedhamMaintainsBuy—
2 July 2026MizuhoMaintainsOutperform—
29 June 2026B of A SecuritiesDowngradeUnderperform—
29 June 2026Wells FargoMaintainsOverweight—
24 June 2026NeedhamMaintainsBuy—
22 June 2026TD CowenMaintainsBuy—
18 June 2026NeedhamMaintainsBuy—
9 June 2026RBC CapitalMaintainsOutperform—
13 May 2026BairdMaintainsOutperform—
6 May 2026NeedhamMaintainsBuy—
6 May 2026UBSMaintainsBuy—
6 May 2026Wells FargoMaintainsOverweight—
9 Apr 2026B of A SecuritiesMaintainsNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALKS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ALKS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Alkermes Plc returned +65.9% against +17.5% for the S&P 500, dividends included.

ALKS vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160180200Oct 25Jan 26Apr 26Jul 26ALKSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALKS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2024.7%
Analysts raising
1
Analysts cutting
1
Fundamentals

Alkermes Plc (ALKS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
121.0×

Cheaper than 6% of US stocks

Price / sales
4.6×

Cheaper than 27% of US stocks

Price / book
4.3×

Cheaper than 24% of US stocks

EV / EBITDA
30.3×

Cheaper than 9% of US stocks

Growth & margins
Revenue growth (YoY)
27.0%

Higher than 76% of US stocks

Earnings growth (YoY)
−99.4%

Higher than 2% of US stocks

Gross margin
84.3%

Higher than 93% of US stocks

Operating margin
15.5%

Higher than 73% of US stocks

Net margin
4.0%

Higher than 57% of US stocks

Returns & dividend
Return on equity
3.9%

Higher than 52% of US stocks

Return on assets
4.2%

Higher than 72% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alkermes Plc (ALKS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alkermes Plc has a market value of $7.7B and an enterprise value of $8.6B.

  • Revenue in the twelve months to 31 Mar 2026: $1.6B. The latest quarter grew 27.0% year on year.

  • Net income over the same four quarters: $152.7M, a 9.8% net margin.

  • Diluted earnings per share, trailing twelve months: $0.90.

  • Free cash flow in the twelve months to 31 Mar 2026: $221.8M, after $35.0M of capital spending.

  • Alkermes Plc spent $27.7M on share buybacks in the twelve months to 31 Mar 2026.

  • Shares outstanding: 167.8M.

  • Trailing P/E: 121.0×; forward P/E: 25.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Alkermes Plc employs 2,050 people — $762K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

ALKS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDrug Manufacturers - Specialty & Generic
CompanyMarket capTKN rank
ALKSAlkermes Plc$7.7B
62
LNTHLantheus Holdings, Inc.$6.5B
88
HIMSHims & Hers Health, Inc.$6.4B
17
LQDALiquidia Corp.$6.0B
78
KNSAKiniksa Pharmaceuticals International Plc$5.9B
98
AMRXAmneal Pharmaceuticals, Inc.$5.3B
83
ELANElanco Animal Health, Inc.$11.6B
98

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alkermes Plc — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALKS news & analysis

Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise

Seeking Alpha · 11 Sept 2026positive

Seeking Alpha reports that Alkermes plc was upgraded from Hold to Buy, citing robust revenue growth, pipeline momentum in sleep and CNS disorders, and the Avadel acquisition with the Lumryz launch driving over 20% revenue growth in 2026. The article also notes strong Phase 2 data for Alixorexton in narcolepsy and idiopathic hypersomnia and an advancing orexin pipeline, set against adjusted EBITDA guidance of $370–410M and a GAAP net loss.

Why it matters — Alkermes watchers would care because the article highlights the company's revenue acceleration from Lumryz and its growing orexin pipeline as key drivers of its long-term CNS and sleep-disorder positioning.

Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program

Business Wire · 10 Sept 2026positive

Alkermes announced it will begin accepting applications for its ninth annual Alkermes Pathways Research Awards program on Sept. 11, 2026. The competitive grant program supports early-career researchers advancing understanding of diseases in neuroscience.

Why it matters — The program signals Alkermes' ongoing investment in neuroscience research and its commitment to fostering the next generation of researchers in a key therapeutic area.

Alkermes Chief Commercial Officer Sells 7,576 Shares for $373,000

The Motley Fool · 29 Aug 2026neutral

Alkermes' Chief Commercial Officer sold 7,576 shares, generating approximately $373,000 in proceeds. The transaction reduced the executive's direct equity holdings by 7%.

Why it matters — ALKS watchers would care because insider selling can be a signal about management sentiment regarding the company's stock.

Why Is Alkermes (ALKS) Up 1.7% Since Last Earnings Report?

Zacks Investment Research · 27 Aug 2026neutral

Alkermes reported its quarterly earnings 30 days ago, and its stock has risen 1.7% since that report. The article examines what may come next for the company's shares following the earnings announcement.

Why it matters — The piece provides context on how Alkermes shares have performed since its latest earnings report, which is relevant for investors tracking the company's recent financial results.

The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1

Business Wire · 24 Aug 2026positive

Alkermes announced that data from its Vibrance-1 phase 2 study of alixorexton, an investigational oral selective orexin 2 receptor agonist, in adults with narcolepsy type 1 were published in The Lancet Neurology. The results were described as positive.

Why it matters — This peer-reviewed publication of positive phase 2 data supports the advancement of alixorexton, a key pipeline candidate for Alkermes in narcolepsy and related sleep disorders.

FAQ

Frequently asked questions about ALKS stock

What is the ALKS stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Alkermes Plc have a median 12-month price target of $58, with estimates ranging from $38 to $72. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALKS stock a buy right now?

Of the 18 analysts covering Alkermes Plc, 14 rate it a Buy, 3 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Alkermes Plc 62 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALKS?

As at 12 Sept 2026, Alkermes Plc ranks 62 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (98 of 100).

Will ALKS stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +26.2% from the last close, and Ticker Nerd's factor model ranks Alkermes Plc 62 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALKS stock forecast for 2030?

No analyst covering Alkermes Plc publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALKS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $38 to $72 over the next 12 months.

How has ALKS stock performed over the past year?

Alkermes Plc returned +65.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alkermes Plc do?

Alkermes plc is a global biopharmaceutical company focused on developing, manufacturing, and commercializing medicines for central nervous system disorders and other serious conditions. Its current portfolio includes treatments for schizophrenia, bipolar I disorder, alcohol dependence, opioid dependence, and narcolepsy-related symptoms, with products such as ARISTADA, ARISTADA INITIO, VIVITROL, LYBALVI, and LUMRYZ.

What is the latest news on ALKS?

The most recent item we track (Seeking Alpha, 11 Sept 2026): "Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise". Seeking Alpha reports that Alkermes plc was upgraded from Hold to Buy, citing robust revenue growth, pipeline momentum in sleep and CNS disorders, and the Avadel acquisition with the Lumryz launch driving over 20% revenue growth in 2026. The article also notes strong Phase 2 data for Alixorexton in narcolepsy and idiopathic hypersomnia and an advancing orexin pipeline, set against adjusted EBITDA guidance of $370–410M and a GAAP net loss.

Company

About Alkermes Plc.

Alkermes plc is a global biopharmaceutical company focused on developing, manufacturing, and commercializing medicines for central nervous system disorders and other serious conditions. Its current portfolio includes treatments for schizophrenia, bipolar I disorder, alcohol dependence, opioid dependence, and narcolepsy-related symptoms, with products such as ARISTADA, ARISTADA INITIO, VIVITROL, LYBALVI, and LUMRYZ. The company works across research, clinical development, and product commercialization, using its drug formulation and delivery capabilities to support therapies designed for complex and chronic illnesses. Alkermes plc serves patients, healthcare providers, and healthcare systems in the United States, Ireland, and international markets. Founded in 1987 and headquartered in Dublin, Ireland, the company holds a notable position in the neuroscience-focused biopharmaceutical sector.

CEO Mr. Blair C. Jackson · 2,050 employees · Ireland · https://www.alkermes.com